Previous investigators have reported that BAP1 mutations occur in approximately 10% of ccRCC tumors [1, 2, 4] and loss of BAP1 expression is associated with reduced survival [1]. This evidence concerns the gene BAP1 and nonpapillary renal cell carcinoma.